ERBB2 and breast carcinoma: Based on the clinical activity observed in the EGF104900, LANDSCAPE, and EMILIA studies, the most active treatment options for HER2-positive breast cancer patients with brain metastases include trastuzumab/lapatinib [28], capecitabine/lapatinib [29], and TDM-1 [24].